Articles Referencing IND
Market Trends Offer Opportunities for FPMI - Analyst Blog
5/20/2013, 1:01 pm from Zacks.com in Investing, Business, Stocks
FluoroPharma Medical, Inc. (OTC BB:FPMI) seeks to develop
breakthrough molecular imaging agents for positron emission
tomography (PET) to fulfill critical medical needs. The company's
products... Read >>
Wider-than-Expected Loss at Endocyte - Analyst Blog
5/6/2013, 2:18 pm from Zacks.com in Investing, Business, Stocks
Endocyte, Inc. ( ECYT ) reported first
quarter 2013 net loss per share of 11 cents, wider than the Zacks
Consensus Estimate of a loss of 5 cents but narrower than the
year-ago loss... Read >>
Loss Widens at Momenta - Analyst Blog
5/2/2013, 9:57 am from Zacks.com in Investing, Business, Stocks
Momenta Pharmaceuticals Inc. ( MNTA ) reported first
quarter 2013 net loss per share of 48 cents, wider than the Zacks
Consensus Estimate of a loss of 43 cents and the year-ago loss of
10... Read >>
AZN/BIND Therapeutics Ink Deal - Analyst Blog
4/23/2013, 7:11 pm from Zacks.com in Investing, Business, Stocks
AstraZeneca ( AZN ) recently
announced that it has entered into an agreement with BIND
Therapeutics for the development and commercialization of Accurin
(a cancer nanomedicine).
As per... Read >>
ImmunoGen to Focus on Pipeline - Analyst Blog
4/15/2013, 7:05 pm from Zacks.com in Investing, Business, Stocks
ImmunoGen Inc. ( IMGN ) recently
provided an update on its pipeline and maintained its outlook for
fiscal year 2013 (ending June 30) at its recently held Analyst
& Investor Day. ... Read >>
ADC Data from Seattle Genetics - Analyst Blog
4/10/2013, 6:08 pm from Zacks.com in Investing, Business, Stocks
Seattle Genetics Inc. ( SGEN ) recently
presented data on its antibody-drug conjugate (ADC) candidates at
the annual meeting of the American Association for Cancer Research
(AACR). ... Read >>
Idenix Reports In-Line 4Q Loss - Analyst Blog
3/1/2013, 10:08 am from Zacks.com in Investing, Business, Stocks
Idenix Pharmaceuticals' ( IDIX ) loss of 17
cents per share in the fourth quarter of 2012 was a penny below the
year-ago loss and in-line with the Zacks Consensus Estimate. The company's... Read >>
Loss at MNTA Narrower than Expected - Analyst Blog
2/19/2013, 4:29 pm from Zacks.com in Investing, Business, Stocks
Momenta Pharmaceuticals Inc. ( MNTA ) reported fourth
quarter 2012 net loss per share of 35 cents, narrower than the
Zacks Consensus Estimate of a loss of 41 cents, but wider than... Read >>
Pipeline Setback for Idenix - Analyst Blog
2/7/2013, 5:10 pm from Zacks.com in Investing, Business, Stocks
Idenix Pharmaceuticals, Inc. ( IDIX ) recently
announced that the company has decided to discontinue its clinical
development program for IDX184.
IDX184 is a nucleotide polymerase... Read >>
Pipeline Progress at Endocyte - Analyst Blog
1/31/2013, 6:30 pm from Zacks.com in Investing, Business, Stocks
Endocyte Inc. ( ECYT ) recently
announced that its oncology candidate, EC0652, achieved key
objectives in a phase 0 study. Endocyte is developing the candidate
as a treatment of patients... Read >>
Wider Loss at ImmunoGen - Analyst Blog
1/28/2013, 9:16 am from Zacks.com in Investing, Business, Stocks
ImmunoGen Inc. ( IMGN ) reported second
quarter fiscal 2013 adjusted loss of 29 cents per share, wider than
both the Zacks Consensus Estimate of a loss of 24 cents and the
year-ago loss of... Read >>
Infinity Provides Pipeline Update - Analyst Blog
1/11/2013, 12:20 pm from Zacks.com in Investing, Business, Stocks
Infinity Pharmaceuticals Inc. ( INFI ) recently
provided an update on its pipeline and issued its guidance for
2013. The company expects to report data from both its development
programs -... Read >>
ING Group, N.V. (IND) Ex-Dividend Date Scheduled for November 28, 2012
11/26/2012, 9:00 am from NASDAQ.com News in News Headlines, Stocks
ING Group, N.V. ( IND ) has announced an
ex-dividend date of November 28, 2012 and a cash dividend payment
of $0.4406 per share scheduled for December 15, 2012. Shareholders
who purchased IND... Read >>
Alnylam Reveals ALNTTR01 Trial Data - Analyst Blog
11/25/2011, 1:00 pm from Zacks.com in Investing, Business, Stocks
Alnylam Pharmaceuticals Inc.
(
ALNY
) recently presented data from an early stage study of its pipeline
candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01
is a... Read >>
A Dividend-Producing Income Stock
4/1/2010, 12:38 pm from Cabot Heritage Corporation in Investing, Stocks
Today, I'd like to discuss the New York City subway, one of the
most impressively complex in the world. Of course, I live in New
York, so I'm hardly impartial.
The New York City subway has... Read >>